| Autor: |
Stephanie A, Harmon, Ethan, Bergvall, Esther, Mena, Joanna H, Shih, Stephen, Adler, Yolanda, McKinney, Sherif, Mehralivand, Deborah E, Citrin, Anna, Couvillon, Ravi A, Madan, James L, Gulley, Ronnie C, Mease, Paula M, Jacobs, Martin G, Pomper, Baris, Turkbey, Peter L, Choyke, M Liza, Lindenberg |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 59(11) |
| ISSN: |
1535-5667 |
| Popis: |
The purpose of this study was to compare the diagnostic performance of (18)F-DCFBC PET/CT, a first-generation (18)F-labeled prostate-specific membrane antigen (PSMA)–targeted agent, and (18)F-NaF PET/CT, a sensitive marker of osteoblastic activity, in a prospective cohort of patients with metastatic prostate cancer. Methods: Twenty-eight prostate cancer patients with metastatic disease on conventional imaging prospectively received up to 4 PET/CT scans. All patients completed baseline (18)F-DCFBC PET/CT and (18)F-NaF PET/CT scans, and 23 patients completed follow-up imaging, with a median follow-up interval of 5.7 mo (range, 4.2–12.6 mo). Lesion detection was compared across the 2 PET/CT agents at each time point. Detection and SUV characteristics of each PET/CT agent were compared with serum prostate-specific antigen (PSA) levels and treatment status at the time of baseline imaging using nonparametric statistical testing (Spearman correlation, Wilcoxon rank). Results: Twenty-six patients had metastatic disease detected on (18)F-NaF or (18)F-DCFBC at baseline, and 2 patients were negative on both scans. Three patients demonstrated soft tissue–only disease. Of 241 lesions detected at baseline, 56 were soft-tissue lesions identified by (18)F-DCFBC only and 185 bone lesions detected on (18)F-NaF or (18)F-DCFBC. (18)F-NaF detected significantly more bone lesions than (18)F-DCFBC (P < 0.001). Correlation of PSA with patient-level SUV metrics was strong in (18)F-DCFBC (ρ > 0.5, P < 0.01) and poor in (18)F-NaF (ρ < 0.3, P > 0.1). When PSA levels were combined with treatment status, patients with below-median levels of PSA ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
